Adaptive Biotechnologies

Yahoo Finance • 3 days ago

Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings

[Heart Health Concept] Eoneren/E+ via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary laggards, with the Health Care Select Sector SPDR Fund (XLV [https://se... Full story

Yahoo Finance • 6 days ago

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On

Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation(NASDAQ:ADPT), reported the sale of 38,120 shares of Common Stock for approximately $554,000 in a set of transactions executed on April 1, 2026 and April 2, 202... Full story

Yahoo Finance • 29 days ago

Is Merck & Co., Inc. (MRK) A Good Stock To Buy Now?

Is MRK a good stock to buy now? We came across a bullish thesis on Merck & Co., Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.'s share was trading at $117.11 as of March 9th.... Full story

Yahoo Finance • 2 months ago

Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside. On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, w... Full story

Yahoo Finance • 2 months ago

Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ...

This article first appeared on GuruFocus. Total Revenue: $277 million for the full year, representing 55% year-over-year growth. MRD Revenue: $212 million for the full year, up 46% year-over-year. Immune Medicine Revenue: $23.4 million fo... Full story

Yahoo Finance • 3 months ago

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clini... Full story

Yahoo Finance • 4 months ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Adaptive Biotechnologies A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and developm... Full story

Yahoo Finance • 4 months ago

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose... Full story

Yahoo Finance • 4 months ago

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose... Full story

Yahoo Finance • 5 months ago

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose... Full story

Yahoo Finance • 5 months ago

Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here’s Why

We recently published 10 Big Names Crushing the Market. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best-performing stocks on Friday. Adaptive Biotechnologies soared to a new three-year high on Friday, as investors re... Full story

Yahoo Finance • 5 months ago

Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the lette... Full story

Yahoo Finance • 6 months ago

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose... Full story

Yahoo Finance • 6 months ago

Cathie Wood's Ark Invest weekly recap: sheds shares in Palantir Technologies, Shopify, Roblox

Wall Street's mood soured last week after U.S. President Donald Trump threatened higher tariffs to China, saying it had "become very hostile" sending letters to other countries wanting to "impose export controls." Major averages plummeted... Full story

Yahoo Finance • 8 months ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose... Full story

Yahoo Finance • 8 months ago

Adaptive Biotechnologies (NASDAQ:ADPT) Fits Minervini's Trend Template with Strong Growth Momentum

Adaptive Biotechnologies Corp. (NASDAQ:ADPT [https://www.chartmill.com/stock/quote/ADPT]) has been recognized as a possible choice for investors using Mark Minervini’s trend-based approach and high-growth momentum investing. The Minervini... Full story

Yahoo Finance • 8 months ago

Piper Sandler raises Adeptus Biotechnologies stock price target on growth outlook

Investing.com - Piper Sandler raised its price target on Adeptus Biotechnologies Corp. (NASDAQ:ADPT) to $15.00 from $13.00 on Wednesday, while maintaining an Overweight rating on the stock. The company, currently valued at $1.73 billion, h... Full story

Yahoo Finance • 8 months ago

Adaptive Biotechnologies soars 8.5% as MRD business achieves profitability

Investing.com -- Adaptive Biotechnologies Corp (NASDAQ:ADPT) shares surged 8.5% after the company reported second quarter results that significantly exceeded analyst expectations, driven by strong performance in its Minimal Residual Dise... Full story

Yahoo Finance • 8 months ago

Cathie Wood's ARK ETFs shuffle RBLX, COIN, and BMNR stocks

Cathie Wood’s ARK ETFs have made significant moves in the stock market on Friday, August 1, 2025, with a particular focus on tech and biotech companies. Leading the trades was a massive purchase of Coinbase Global Inc (NASDAQ:COIN) share... Full story

Yahoo Finance • 9 months ago

Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market regained its strength in the second quar... Full story